STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
Status:
Completed
Trial end date:
2003-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: STI571 may interfere with the growth of cancer cells and may be effective
treatment for chronic myelogenous leukemia.
PURPOSE: Phase II trial to study the effectiveness of STI571 in treating patients who have
chronic myeloid leukemia that has not responded to interferon alfa.